Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
The Natural History of Recurrent Optic Neuritis
Arch Neurol 61:1401-1405, Pirko,I.,et al, 2004
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Risk Factors for Developing Multiple Sclerosis after Childhood Optic Neuritis
Neurol 49:11413-1418, Lucchinetti,C.F.,et al, 1997
Optic Neuritis:A Population-Based Study in Olmsted County, Minnesota
Neurol 45:244-250, Rodriquez,M.,et al, 1995
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Uhthoff's Symptom in Optic Neuritis:Relationship to Magnetic Resonance Imaging & Development of Multiple Sclerosis
Ann Neurol 30:180-184, Scholl,G.B.,et al, 1991
Central Lesions in Chronic Inflammatory Demyelinating Polyneuropathy:An MRI Study
Neurol 40:476-478, Feasby,T.E.,et al, 1990
A Long-Term Prospective Study of Optic Neuritis:Evaluation of Risk Factors
Ann Neurol 27:386-393, Sandberg-Wollheim,M.,et al, 1990
Cranial Magnetic Resonance Imaging in Chronic Demyelinating Polyneuropathy
JNNP 53:794-796, Hawke,S.H.B.,et al, 1990
Involvement of the CNS in Chronic Inflammatory Demyelinating Polyneuropathy:A Clinical Electrophys & MRI Study
JNNP 53:789-793, Ormerod,I.E.C.,et al, 1990
Evoked Potentials in Chronic Inflammatory Demyelinating Polyneuropathy
Arch Neurol 45:1014-1016, Pakalnis,A.,et al, 1988
Optic Neuritis in the Elderly:Prognosis for Visual Recovery and Long-Term Follow-Up
Neurol 38:1834-1837, Jacobson,D.M.,et al, 1988
Evidence for Central Nervous System Demyelination in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Neurol 37:1291-1294, Mendell,J.R.,et al, 1987
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
The Geography of Neurology
BMJ 2:506, Spillane,J.D., 1972
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Prodromal Symptoms of Multiple Sclerosis in Primary Care
Ann Neurol 83:1162-1173, Disanto,G.,et al, 2018
Inclusion of Optic Nerve Involvement in Dissemination in Space Criteria for Multiple Sclerosis
Neurol 91:e1130-e1134,545, Brownlee, W.J.,et al, 2018
Foot Drop
WebMD, Bernstein, L., 2018
Numb Chin Syndrome
UptoDate.com Sept, Robertson, C.E., 2018
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Relapsing-Remitting Tumefactive Demyelination
JAMA Neurol 71:366-367, Brandao, E.,et al, 2014
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014
Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013
Clinical Features of MS Associated with Leber Hereditary Optic Neuropathy mtDNA Mutations
Neurol 81:2073-2081, Pfeffer, G.,et al, 2013
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
The Differential Diagnosis of Longitudinally Extensive Transverse Myelitis
Mult Scler 18:271-285, Kitley, J.L.,et al, 2012
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Longitudinal Study of Vision and Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Ann Neurol 67:749-760, Talman,L.S., et al, 2010
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010
Early MRI in Optic Neuritis: The Risk for Disability
Neurol 72:542-550, Swanton,.K.,et al, 2009
Pediatric Optic Neuritis: Brain MRI Abnormalities and Risk of Multiple Sclerosis
Neurol 72:881-885, Bonhomme,G.R.,et al, 2009
Clinicopath Conf, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
NEJM 360:1656-1665, Case 12-2009, 2009
Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008
4-Aminopyridine Toxicity with Unintentional Overdose in Four Patients with Multiple Sclerosis
Neurol 71:1833-1834, Burton,J.M.,et al, 2008
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
What Do We Really See When We Look at Magnetic Resonance Images?
Ann Neurol 62:207-208, Filippi,M. &Hartung,H.-P., 2007
The Clinical Features, MRI Findings, and Outcome of Optic Neuritis in Children
Neurol 67:258-262, Wilejto,M.,et al, 2006
Is Optic Neuritis More Benign Than Other First Attacks in Multiple Sclerosis?
Ann Neurol 57:210-215, Tintore, M., et al, 2005